NCT07645469
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Oct 15, 2026 to Dec 1, 2026
Notable Start date: Sep 1, 2026 to Oct 15, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 5 words
- Interventions: Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells (Drug), Azacitidine (Drug), Biospecimen Collection… to Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells (Drug), Azacitidine (Drug), Biospecimen Collection…
- Study description revised
- Site details revised
- Notable Eligibility criteria expanded, about 10 wordsv4
- Notable Start date: Aug 1, 2026 to Sep 1, 2026v3
- Notable Recruitment opened
- Start date: Oct 1, 2026 to Aug 1, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (2)
Arms and interventions
Patients undergo leukapheresis. 4 weeks later patients receive azacitidine IV. At least 4 weeks after the first azacitidine infusion, patients receive azacitidine IV followed by FH-WT1-E50 TCR T cells IV. If additional cells are available patients may receive a second infusion of azacitidine IV followed by FH-WT1-E50 TCR T cells IV, starting at 28 days, up to 1 year. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo MUGA scan/echocardiography and chest x-ray during screening and bone marrow biopsy and aspiration and blood sample collection throughout the study. Patients may undergo lumbar puncture on study and CT scan and/or PET scan throughout the study.
Drugs: Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine
Procedures: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Echocardiography Test, Lumbar Puncture, Multigated Acquisition Scan, Positron Emission Tomography
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States